Every material Form 8-K Serina Therapeutics, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Serina Therapeutics reported that an independent Safety Monitoring Committee completed a blinded review of Cohort 1 in its Phase 1b study of SER-252 in advanced Parkinson's disease and recommended advancing to Cohort 2. Blinded Cohort 1 data at the lowest dose showed a pharmacokinetic profile consistent with sustained apomorphine exposure and sustained motor improvement in some individual patients on exploratory measures. The company expects topline data from the single-ascending-dose portion in the first half of 2027, but the Cohort 1 data are preliminary, blinded, exploratory and based on a small number of patients.
Cohort 1 enrolled eight patients, randomized 3:1 to SER-252 or placebo, and evaluated the lowest dose level.
The Independent Safety Monitoring Committee recommended advancing to Cohort 2 based on blinded safety and tolerability data.
Serina expects to report topline data from the single-ascending-dose portion of the study in the first half of 2027.
The filing states Cohort 1 data are preliminary, blinded, and exploratory and may not be evidence of treatment effect.
Serina Therapeutics entered into a Common Stock Purchase Agreement and a Registration Rights Agreement with Roth Principal Investments, both dated August 21, 2026. The company can choose, at its sole discretion, to sell up to $25 million of newly issued common stock over up to 36 months, so the deal gives it a funding option while adding potential dilution at prices set below market.
Agreement dated August 21, 2026 allows the company to sell up to $25 million of newly issued common stock to Roth Principal Investments, at the company's option and with no obligation to sell.
Purchases are priced at a discount to volume weighted average price: 7% before cumulative sales reach $12.5 million and 3% after, for market open and intraday purchases.
Under NYSE American rules, issuance is capped at 5,077,554 shares, equal to 19.99% of shares outstanding before signing, unless stockholders approve more or other conditions are met.
Sales can begin only after a resale registration statement is declared effective by the SEC, and the company may direct purchases for up to 36 months from that Commencement Date.
Serina Therapeutics reported second quarter 2026 results with a net loss attributable to common shareholders of $8.9 million, up from $6.6 million a year earlier, while the per-share loss narrowed to $(0.55) from $(0.66) on a larger share count. The company said it completed enrollment and dosing in Cohort 1 of the SER-252 Phase 1b registrational study in July 2026, ahead of its prior guidance, with top-line data still targeted for the first half of 2027.
Net loss attributable to common shareholders was $8.9 million, or $(0.55) per share, for Q2 2026, versus $6.6 million, or $(0.66) per share, for Q2 2025.
No revenue was reported in Q2 2026, compared with $130 thousand in Q2 2025; total operating expenses rose to $6.8 million from $5.7 million.
Cash and cash equivalents totaled $23.0 million as of June 30, 2026.
Cohort 1 of SER-252 completed enrollment and dosing in July 2026, ahead of guidance for the end of Q3 2026; top-line data are targeted for the first half of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Serina Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →